Witney Frank 4

What Happened
Witney Frank, a director of Standard BioTools, was granted two equity awards on June 18, 2026: 99,116 restricted stock units (RSUs) and 175,923 derivative RSUs (both reported at $0.00 acquisition price). These awards are grants (not open‑market purchases or sales) and will convert into shares only upon vesting; no cash was paid by the reporting person.

Key Details

• Transaction date: June 18, 2026; Form 4 filed June 23, 2026 (filed one business day late versus the typical 2‑business‑day deadline).
• Awards reported: 99,116 RSUs (non‑derivative) and 175,923 derivative RSUs (both $0.00 acquisition price).
• Shares owned after transaction: not specified in the excerpt provided.
• Footnotes of note:
  • F1: The RSUs vest in full on the earlier of June 18, 2027 or one day before the company's next annual meeting, subject to continued service; each RSU converts to one share upon vesting.
  • F2: Some shares are held indirectly by a family trust (First Amended and Restated Revocable Trust Agreement for Franklin R. Witney and Catherine J. Caulfield‑Witney).
  • F3: The filing references an option schedule that becomes exercisable in 12 equal monthly installments beginning July 18, 2026 (appears to describe a separate award/exercise schedule referenced in the filing).

Context

• These are grants/awards (code A) and do not represent an immediate purchase or sale; they are common compensation for directors and depend on continued service to vest.
• Derivative/RSU awards indicate potential future dilution when they vest and convert to shares; they do not necessarily signal the insider’s near‑term market view.
• The filing was submitted one business day after the likely Form 4 due date, which is worth noting for timeliness but does not change the nature of the awards.